Rheumaderm pp 73-83 | Cite as

Systemic Sclerosis

A Clinical Overview
  • S. Generini
  • G. Fiori
  • A. Moggi Pignone
  • M. Matucci Cerinic
  • M. Cagnoni
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)


Systemic Sclerosis (SSc) is a multisystem disease that affects the skin and internal organs (i.e., gastrointestinal tract, lung, heart, kidney and peripheral nervous system). In the early phase, lung involvement is characterized by interstitial inflammatory alterations that are detected by bronchoalveolar lavage analysis and high resolution computed tomography (ground glass). As the disease progresses, fibrotic changes become evident and the diffusing capacity for carbon monoxide (DLCO) is impaired. Cardiac involvement in SSc can be manifested as myocardial disease, pericardial disease, conduction system disease, or arrhytmias. Cardiac involvement is a poor prognostic factor, but the diagnosis may be late or missing because of the frequent discrepancy between clinical manifestations and the real cardiac involvement. For this reason, resort to all the available diagnostic procedures is recomended to achieve an early diagnosis. The motility disorders are a major feature of gastrointestinal involvement in SSc, striking any part of this system (especially esophagus and anorectal region). Kidney involvement and scleroderma renal crisis are now considered rare because of the introduction of ACE inhibitors. Some patients may develop myositis or erosive arthropathy that complicate enormously the joint retraction induced by skin fibrosis. The peripheral nervous system (PNS) is also targeted by SSc: a distal mononeuropathy of the median nerve is a frequent and early feature; autonomic nerve dysfunction (parasympathetic impairment and marked sympathetic overactivity) seems to be a fundamental etiologic factor linked to the development of microvascular, cardiac and gastrointestinal alterations.

The whole approach to the SSc patient is very complex and must consider, at the same time, many organs and systems. Thus, a global vision of SSc patient is needed in order to assure an early diagnosis of specific organ involvement as well as early treatment.

Systemic Sclerosis (SSc) is a multisystem disease, that affects the skin, the gastrointestinal tract, the lung, the heart and the kidney. The extent and severity of internal organ involvement are the more important factors influencing the disease outcome and prognosis in SSc. In recent years, it has become evident that early diagnosis and accurate staging of visceral involvement are fundamental for appropriate management and therapeutic approach to the disease.

Diagnostic procedures for specific organ and system involvement are now more sensitive because of the continuous technological improvement and, mostly, because they take advantage of the studies carried out in other diseases by other medical branches. This review will consider briefly the most frequent and important organ involvement in SSc.


Idiopathic Pulmonary Fibrosis Systemic Sclerosis Carpal Tunnel Syndrome High Resolution Compute Tomography Scleroderma Renal Crisis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pignone A, Matucci Cerinic M, Lombardi A, Fedi R, Fargnoli R, De Dominicis R, Cagnoni M: High Resolution computed in Systemic Sclerosis. Real diagnostic utilities in the assessment of pulmonary involvement and comparison with other modalities of lung investigation. Clin Rheumatol 11: 465–4-72. 1992PubMedCrossRefGoogle Scholar
  2. 2.
    Silver RM, Scott Miller K: Lung involvement in Systemic Sclerosis. Rheum Dis Clin N Am 16: 199–216. 1990Google Scholar
  3. 3.
    Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, du Bois RM: The Predictive value of Appearances on Thin-section Computed Tomography in Fibrosing Alveolitis. Am Rev Respir Dis 148: 1076–1082. 1993PubMedCrossRefGoogle Scholar
  4. 4.
    Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM, du Bois RM: Fibrosing alveolitis in Systemic Sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthitis Rheum 40: 1229–1236. 1997Google Scholar
  5. 5.
    Dévényi K, Czirjak L: High Resolution Computed Tomography for the Evaluation of Lung Involvement in 101 Patients with Scleroderma. Clin Rheumat 14: 633–640. 1995CrossRefGoogle Scholar
  6. 6.
    Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, du Bois RM: High Resolution Computed Tomography as a predictor of lung Histology in Systemic Sclerosis. Thorax 47: 738–742. 1992PubMedCrossRefGoogle Scholar
  7. 7.
    Warrick JH, Meenakshi Bhalla, Schabel SI, Silver RM: High Resolution Computed Tomography in early scleroderma lung disease. J Rheumatol 18: 1520–1528. 1991PubMedGoogle Scholar
  8. 8.
    Agusti C, Xaubet A, Luburich P, Ayuso MC, Roca J, Rodriguez-Roisin R: Computed tomography-guided bronchoalveolar lacage in idiopathic pulmonary fibrosis. Thorax 51: 841–845. 1996PubMedCrossRefGoogle Scholar
  9. 9.
    Silver RM: Interstitial Lung Disease of Systemic Sclerosis. Intern Rev Immunol 12: 281–291. 1995CrossRefGoogle Scholar
  10. 10.
    Silver RM: Clinical Problems: The Lung. Rheum Dis Clin N Am 22: 825–840. 1996CrossRefGoogle Scholar
  11. 11.
    Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM: Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 40: 743–751. 1997PubMedCrossRefGoogle Scholar
  12. 12.
    Wells AU, Hansell DM, Rubens MB, Cullinan P, Haslam PL, Black CM, du Bois RM: Fibrosing Alveolitis in Systemic Sclerosis; Bronchoalveolar Lavage Findings in Relation to Computed Tomographic Appearance. Am J Respir Crit Care Med 150: 462–468. 1994PubMedGoogle Scholar
  13. 13.
    Behr J, Volgelmeier C, Beinert T, Meurer M, Krombach F, Konig G, Fruhmann G: Bronchoalveolar Lavage For Evaluation and Management of Scleroderma Disease of the Lung. Am J Respir Crit Care Med 154: 400–406. 1996PubMedGoogle Scholar
  14. 14.
    Clements PL, Furst DE, Cabeen W, Tashkin D, Paulus HE, Roberts N: The relationship of arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis. Am J Med 71: 38–46. 1981PubMedCrossRefGoogle Scholar
  15. 15.
    Deswal A, Follansbee WP: Cardiac involvement in scleroderma. Rheum Dis Clin N Am 22: 841–860. 1996CrossRefGoogle Scholar
  16. 16.
    Medsger TA Jr, Masi AT, Rodnan JP, et al: Survival with systemic sclerosis (scleroderma): A life-table analysis of clinical and demographic factors in 309 patients. Ann Int Med 75: 369–376. 1971PubMedGoogle Scholar
  17. 17.
    Kahan A, Devaux J, Amor B, et al: The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin Pharmacol Ther 47: 483–489. 1990PubMedCrossRefGoogle Scholar
  18. 18.
    Steen VD, Follansbee WP, Conte CG, Medsger TA Jr: Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum 39: 677–681. 1996PubMedCrossRefGoogle Scholar
  19. 19.
    Schwartz PJ, La Rovere MT, Vanoli E: Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation. 85(Suppl 1): 177–191. 1992Google Scholar
  20. 20.
    Ferri C, Emdin M, Giuggioli D, et al: Autonomic dysfunction in Systemic Sclerosis: time and frequency domain 24 hour heart rate variability analysis. Br J Rheum 36: 669–676. 1997CrossRefGoogle Scholar
  21. 21.
    Pignone A, Matucci-Cerinic M, Becucci A et al: Patterns of ventricular late potentials in systemic sclerosis: a noninvasive method in the study of cardiac involvement. Ann Ital Med Int 9: 141–145. 1994PubMedGoogle Scholar
  22. 22.
    Rosada M, Cozzi F, Bullo A, et al: Prevalence of ventricular late potentials in systemic sclerosis and analysis of clinical and 24 hour elettrocardigraphy associations. Reumatismo 49 (suppl. 3): 221. 1997Google Scholar
  23. 23.
    Morelli S, Sgreccia A, De Marzio, et al: Noninvasive assessment of myocardial involvement in patients with systemic sclerosis: role of signal averaged electrocardiography. J Rheumatol 24: 2358–2363. 1997PubMedGoogle Scholar
  24. 24.
    Kahan IJ, Menkes C: Gastrointestinal involvement in systemic sclerosis. Clin Dermatol 12: 259–265. 1994PubMedCrossRefGoogle Scholar
  25. 25.
    Young MA, Rose S, Reynolds JC: Gastrointestinal manifestations of scleroderma. Rheum Dis Clin N Am 22: 797–823. 1996CrossRefGoogle Scholar
  26. 26.
    Greydanus MP, Camilleri M: Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology 96: 110–115. 1989PubMedGoogle Scholar
  27. 27.
    Akesson A, Ekman R, Prytz H, Sundler F: tissue concentrations of gastrointestinal regulatory peptides in the duodenal mucosa in systemic sclerosis. Clin Exp Rheumatol 16: 141–148. 1998PubMedGoogle Scholar
  28. 28.
    Rohrmann CA Jr, Ricci MT, Krihnamurthy S, et al: Radiologic and histologic differentiation of neuromuscolar disorders of the gastrointestinal tract. Visceral myopathies, visceral neuropathies, and progressive systemic sclerosis. AJR 143: 933–941. 1981Google Scholar
  29. 29.
    Bassotti G, Battaglia E, Debernardi V, et al: Esophageal dysfunction in scleroderma: relationship with disease subsets. Arthritis Rheum 40: 2252–2259. 1997PubMedCrossRefGoogle Scholar
  30. 30.
    Schima W, Stacher G, Pokieser P, et al: Esophageal motor disorders: videofluoroscopic and manometric avaluation-prospective study in 88 symptomatic patients. Radiology 185: 487–491. 1992PubMedGoogle Scholar
  31. 31.
    Miller LS, Liu JB, Klenn PJ, et al: Endoluminal ultrasonography of the distal esophagus in systemic sclerosis. Gastroenterology. 105: 31–39. 1993PubMedGoogle Scholar
  32. 32.
    Manolios N, Eliades C, Duncombe V, Spencer D: Scleroderma and watermelon stomach. J Rheumatol 23: 776–778. 1996PubMedGoogle Scholar
  33. 33.
    Corazza GR, Di Sabatino A, Brusco G, Di Stefano M: Malabsorption in systemic sclerosis. Clin Exp Rheumatol 16 (suppl), in press. 1998Google Scholar
  34. 34.
    Sjögren RW: Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 9: 1265–1282. 1994CrossRefGoogle Scholar
  35. 35.
    Strocchi A, Levitt MD: Breath hydrogen measurement of small bowel transit time. In Schuster MM (ed): Atlas of gastrointestinal motility in health and disease. Baltimore, Williams and Wilkins, 1993.Google Scholar
  36. 36.
    Jaffin BW, Chang P, Spiera H: Fecal incontinence in scleroderma. Clinical features, anorectal manometric findings, and their therapeutic implications. J Clin Gastroenterol 25: 513–517. 1997PubMedCrossRefGoogle Scholar
  37. 37.
    Traub YN, Shapiro AP, Rodnan GP, et al: Hypertention and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine 62: 335–352. 1983PubMedCrossRefGoogle Scholar
  38. 38.
    Chapman PJ, Pascoe MD, Van Zyl-Smit R: Successful use of captopril in the treatment of “scleroderma renal crisis”. Clin Nephrol 26: 106–108. 1986PubMedGoogle Scholar
  39. 39.
    Steen VD, Medsger TA Jr, Osial TA Jr, at al: Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 76: 779–786. 1984PubMedCrossRefGoogle Scholar
  40. 40.
    Steen VD: Scleroderma renal crisis. Rheum Dis Clin N Am 22: 861–878. 1996CrossRefGoogle Scholar
  41. 41.
    Black CM, Stephens C: Systemic sclerosis (Scleroderma) and related disorders. In Oxford Textbook of Rheumatology, (eds. PJ Maddison, DA Isenberg, P Woo, DN Glass), pp. 771–794. Oxford University Press. 1993Google Scholar
  42. 42.
    Trostle DC, Bedetti CD, Steen VD, et al: Renal vascular histology and morphometry in systemic sclerosis subset: A case-control autopsy study. Arthritis Rheum 3: 393–400. 1988CrossRefGoogle Scholar
  43. 43.
    Generini S, Castellani S, Pellegri M, Matteini M, Pignone A, Matucci Cerinic M: Angiotensin converting enzyme and altered renal autoregulation in Ssc. Arthritis Rheum 40 (suppl): S296. 1997Google Scholar
  44. 44.
    Livi R, Teghini L, Biagini M, Scarpelli PT, Cagnoni M: Renal functional reserve in systemic sclerosis. Clin Exp Rheumatol 16 (suppl), in press. 1998Google Scholar
  45. 45.
    Russell ML: Muscle and nerve in systemic sclerosis (scleroderma). In Systemic sclerosis: scleroderma, 1988 eds. C. M Black and MIV Jayson. Wiley, Chirchester.Google Scholar
  46. 46.
    Follansbee WP, Zerbe TR, Medsger TA: Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): A high risk association Am Heart J 125: 194–203. 1993PubMedCrossRefGoogle Scholar
  47. 47.
    Olsen NJ, King LE, Park JH: Muscle abnormalities in scleroderma. Rheum Dis Clin N Am 22: 783–796. 1996CrossRefGoogle Scholar
  48. 48.
    Hietaharju A, Jaaskelainen S, Kalimo H, Hietarinta M: Peripheral neuromuscular manifestations in systemic sclerosis (scleroderma). Muscle Nerve Nov; 16(11): 1204–1212. 1993CrossRefGoogle Scholar
  49. 49.
    Lori S, Matucci Cerinic M, Casale R, Generini S, Lombardi A, Pignone A, Scaletti C, Gangemi PF, Cagnoni M: Peripheral nervous system involvement in systemic sclerosis: the median nerve as a target structure. Clin Exp Rheumatol 14: 601–605. 1996PubMedGoogle Scholar
  50. 50.
    Matucci Cerinic M, Generini S, Pignone A, Casale R: The nervous system in systemic sclerosis (scleroderma). Rheum Dis Clin N Am 22: 879–892. 1996CrossRefGoogle Scholar
  51. 51.
    Comi G, Comola M, Nemni R, et al: Study of a case of neuropathy associated with progressive systemic sclerosis. Acta Neurol 4: 258–261. 1982Google Scholar
  52. 52.
    Klimiuk PS, Taylor L, Baker RD, et al: Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis 47: 542–545. 1988PubMedCrossRefGoogle Scholar
  53. 53.
    Sonnex C, Paice E, White AG: Autonomic neuropathy in systemic sclerosis: A case report and evaluation of six patients. Ann Rheum Dis 45: 957–960. 1986PubMedCrossRefGoogle Scholar
  54. 54.
    Dessein PHMC, Joffe BL, Metz RM, et al: Autonomic dysfunction in systemic sclerosis: Sympathetic overactivity and instability. Am J Med 93: 143–150. 1992PubMedCrossRefGoogle Scholar
  55. 55.
    Pochas E, Andriotakis C, Kaklamanis P, Antonopoulos M: Joint involvement in systemic lupus erythematosus and in scleroderma (systemic sclerosis). Acta Rheum Scand 13: 137–149. 1967Google Scholar
  56. 56.
    Schumacher HR Jr: Joint and periarticular involvement in systemic sclerosis. Clin Dermatol 12: 277–282. 1994PubMedCrossRefGoogle Scholar
  57. 57.
    Ward M, Cure J, Schabel S, Schabel S, Smith EA, Schumacher HR Jr, Silver RM: Symptomatic spinal calcinosis in systemic sclerosis (scleroderma). Arthritis Rheum 40: 1892–1895. 1997PubMedCrossRefGoogle Scholar
  58. 58.
    Steen VD, Medsger TA Jr: The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum 40: 1146–1151. 1997PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • S. Generini
    • 1
  • G. Fiori
    • 1
  • A. Moggi Pignone
    • 1
  • M. Matucci Cerinic
    • 1
  • M. Cagnoni
    • 1
  1. 1.Department of Medicine Division of RheumatologyUniversity of FlorenceItaly

Personalised recommendations